Skip to main content

Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia

Guinn, Barbara; Jordaens, Stephanie; Cooksey, Leah; Coutinho, Matthew; Van Tendeloo, Viggo; Mills, Ken; Orchard, Kim

Authors

Stephanie Jordaens

Leah Cooksey

Matthew Coutinho

Viggo Van Tendeloo

Ken Mills

Kim Orchard



Abstract

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80 % of cases occur in children where ALL is well understood and treated. However it has a devastating affects on adults, where multi-agent chemotherapy is the standard of care with allogeneic stem cell transplantation for those who are eligible. New treatments are required to extend remission and prevent relapse to improve patient survival rates.
We used serum profiling to compare samples from presentation adult B-ALL patients with age- and sex-matched healthy volunteer (HV) sera and identified 69 differentially recognised antigens (p≤0.02). BMX, DCTPP1 and VGLL4 showed no differences in transcription between patients and healthy donors but were each found to be present at higher levels in B-ALL patient samples than HVs by ICC. BMX plays a crucial role in the Bruton’s Tyrosine Kinase (BTK) pathway which is bound by the BTK inhibitor, ibrutinib, suggesting adult B-ALL would also be a worthy target patient group for future clinical trials.
We have shown the utility of proto-array analysis of B-ALL patient sera, predominantly from young adults, to help characterise the B-ALL immunome and identified a new target patient population for existing small molecule therapy.

Journal Article Type Article
Publication Date 2020-05
Journal British Journal of Haematology
Print ISSN 0007-1048
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 189
Issue 3
Pages 500-512
APA6 Citation Guinn, B., Jordaens, S., Cooksey, L., Coutinho, M., Van Tendeloo, V., Mills, K., & Orchard, K. (2020). Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407
DOI https://doi.org/10.1111/bjh.16407
Keywords acute lymphoblastic leukaemia; antigen identification; serum profiling; immunotherapy; survivin; bone marrow tyrosine kinase on chromosome X (BMX); acute lymphoblastic leukaemia; Ibrutinib; antigen identification; BMX; protein arrays
Publisher URL https://onlinelibrary.wiley.com/journal/13652141
;